Drug-induced exanthem following dabigatran

Area of Science:

• Pharmacology
• Dermatology
• Cardiology

Background:

• Dabigatran is an oral anticoagulant used for preventing thromboembolism in nonvalvular atrial fibrillation.
• The RE-LY trial established dabigatran's efficacy compared to warfarin, with bleeding and GI events as most frequent adverse reactions.
• Hypersensitivity reactions to dabigatran are rare, reported in <0.1% of patients in clinical trials.

Observation:

• A 20-year-old male developed a pruritic, erythematous rash on his inner thigh and forearm after two weeks of dabigatran therapy.
• The exanthem resolved upon discontinuation of dabigatran and initiation of oral corticosteroid treatment.
• Warfarin was subsequently used for thromboembolic prevention.

Findings:

• The Naranjo probability scale indicated a probable relationship between the patient's rash and dabigatran use.
• This case suggests dabigatran can induce exanthematous drug reactions, a rare hypersensitivity manifestation.
• The reaction occurred in a patient without prior exposure to dabigatran.

Implications:

• Clinicians should consider drug-induced exanthem as a potential adverse effect of dabigatran.
• Routine monitoring for hypersensitivity reactions, including skin surveillance, is recommended upon initiating dabigatran therapy.
• This case underscores the need for vigilance regarding rare adverse drug reactions even with established medications.